In our study with cancer genome panel testing, BRCA2 with germline PVs (gPVs) and/or somatic PVs (sPVs) was detected in 395 (395/2361; 16.73%) patients with advanced-stage/metastatic GC. The gene discussed is BRCA2; the disease is cancer.